Failing Health: NDIA’s Annual Vital Signs Report Highlights Weaknesses in the Defense Industrial Base Supply Chain
Client Alert | 1 min read | 02.10.22
The National Defense Industrial Association (NDIA) recently published its 2022 Vital Signs: The Health and Readiness of the Defense Industrial Base report, which includes an analysis of the defense industrial base supply chain. The annual report highlights the degree to which the performance of the supply chain is impacted by external events, namely the COVID-19 pandemic, which in turn impacts internal performance metrics. The report posits that the defense industrial base is not inoculated against the same concerns that have negatively impacted commercial supply chains – i.e., the semiconductor shortage. NDIA researchers analyze four supply chain metrics to conclude that the overall performance of defense supply chains has substantively declined from the previous year and is failing: (1) contract failure; (2) financial performance; (3) inventory performance; and (4) cost management. The report also notes that only 30 out of 245 NDIA members surveyed (12%) indicated that their company’s supplier network would be more reliable at delivering goods, materials and services in the future. The remaining 215 members surveyed (88%) concluded that their company’s supplier networks would be about the same or less reliable. In total, the 2022 Vital Signs report paints a bleak picture of the overall health of the defense industrial base supply chain, and NDIA researchers conclude that next year’s supply chain challenges will be even greater.
For more information on managing supply chain risks, please attend Crowell & Moring’s upcoming webinar:
- Thursday, February 24 – White Collar & Regulatory Enforcement Issues in Supply Chain
Insights
Client Alert | 3 min read | 06.30.25
The New EU “Pharma Package”: Preparing for the Trilogues
On June 4, 2025, after nearly two years of intense debate and negotiation between the 27 EU Member States, the Council of the European Union adopted its position on the proposed overhaul of the EU general pharmaceutical legislative framework known as the new Pharma Package.
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
Client Alert | 3 min read | 06.26.25
Client Alert | 4 min read | 06.26.25
Ninth Circuit Affirms that CIPA Only Applies to Third-Party Eavesdropping